ArticlePharmaceutics2026

EGFR-Targeted Nanoparticle Delivery of Osimertinib for Triple-Negative and Metastatic Breast Cancer Therapy.

Iman M Alfagih et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.